CMOPF: AI 评分 49/100 — AI 分析 (4月 2026)

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on gastroenterology and endoscopy. Founded in 1997, it develops innovative products aimed at improving patient outcomes in gastrointestinal health.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Cosmo Pharmaceuticals N.V. specializes in gastroenterology and endoscopy, offering a diverse portfolio of innovative therapies and diagnostic solutions, positioning itself as a key player in the specialty pharmaceuticals market.

CMOPF是做什么的？

Cosmo Pharmaceuticals N.V., founded in 1997 and headquartered in Dublin, Ireland, is a specialty pharmaceutical company dedicated to developing and commercializing innovative products for gastroenterology and endoscopy. The company has established itself as a leader in the field by offering a range of products designed to enhance patient care and outcomes. Among its notable offerings are Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, which are oral tablet formulations aimed at achieving remission in patients with active, mild to moderate ulcerative colitis. Additionally, Cosmo has developed GI Genius, an advanced artificial intelligence system that aids in the detection of colorectal polyps, and Methylene Blue MMX, a diagnostic drug that improves the detection of precancerous and cancerous colorectal lesions during colonoscopy procedures. The company’s product line also includes Eleview, an injectable composition for gastrointestinal endoscopic procedures, and Aemcolo/Relafalk, which treats various gastrointestinal conditions. Other significant products include Winlevi for acne vulgaris and Clascoterone for androgenetic alopecia. Cosmo Pharmaceuticals has established strategic partnerships, including a licensing agreement with RedHill Biopharma Ltd. and Acacia Pharma Group plc, which further enhances its market reach and product offerings. With a workforce of 321 employees, the company continues to innovate and expand its presence in the global pharmaceutical market.

CMOPF的投资论点是什么？

Cosmo Pharmaceuticals N.V. presents a unique investment thesis driven by its innovative product portfolio and strategic partnerships. The company has a market capitalization of $1.75 billion and a gross margin of 48.5%, indicating strong operational efficiency. Key growth catalysts include the increasing prevalence of gastrointestinal disorders, which is expected to drive demand for its products. Additionally, the company's focus on artificial intelligence in endoscopy through GI Genius positions it well within the evolving healthcare landscape. However, potential risks include its current negative profit margin of -3.5% and the competitive pressures from other pharmaceutical companies in the gastroenterology space. Investors should monitor upcoming product launches and regulatory approvals, which could significantly impact revenue growth in the next 12-24 months.

CMOPF在哪个行业运营？

The drug manufacturing industry, particularly in the gastroenterology sector, is experiencing significant growth driven by an increasing prevalence of gastrointestinal diseases and a rising demand for advanced therapeutic solutions. The global gastroenterology market is projected to expand at a compound annual growth rate (CAGR) of approximately 4.5% over the next five years. Cosmo Pharmaceuticals N.V. competes with companies such as RedHill Biopharma Ltd. (CHIZF), Evotec SE (EVOTF), and others in the specialty pharmaceutical space. The competitive landscape is characterized by rapid innovation and the introduction of new technologies, such as artificial intelligence in diagnostic procedures, which Cosmo is leveraging through its GI Genius product.

Drug Manufacturers - General

Healthcare

CMOPF有哪些增长机遇？

Expansion of GI Genius: The global market for AI-assisted endoscopy is projected to grow significantly, with a market size expected to reach $2 billion by 2028. Cosmo's GI Genius system, which enhances polyp detection, positions the company to capture a significant share of this emerging market, especially as healthcare providers increasingly adopt AI technologies.
Increased Demand for Ulcerative Colitis Treatments: The prevalence of ulcerative colitis is rising, with an estimated market size of $5 billion by 2025. Cosmo's strong portfolio of treatments, including Lialda and UCERIS, places the company in a favorable position to meet this growing demand, particularly as awareness and diagnosis improve.
Geographic Expansion: Cosmo Pharmaceuticals is well-positioned to expand its market presence in emerging markets, where healthcare infrastructure is improving. By targeting regions with increasing healthcare spending, the company can leverage its innovative products to capture new customer segments and drive revenue growth.
Strategic Partnerships: The company's licensing agreements with RedHill Biopharma Ltd. and Acacia Pharma Group plc provide access to additional markets and resources. These partnerships can enhance Cosmo's product offerings and accelerate the development of new therapies, driving long-term growth.
Diversification of Product Portfolio: With ongoing research and development efforts, Cosmo Pharmaceuticals aims to diversify its product line further. The introduction of new drugs targeting conditions such as irritable bowel syndrome and solid tumors could open up additional revenue streams and reduce reliance on existing products.

Market Cap of $1.75 billion, reflecting investor confidence in its innovative product pipeline.
Gross Margin of 48.5%, indicating strong profitability potential compared to industry peers.
Negative Profit Margin of -3.5%, highlighting current operational challenges.
P/E ratio of -408.22, suggesting potential volatility and investor caution.
Dividend Yield of 2.29%, providing income to shareholders despite operational losses.

CMOPF提供哪些产品和服务？

Develops and commercializes innovative pharmaceutical products for gastroenterology and endoscopy.
Offers treatments for ulcerative colitis, including Lialda and UCERIS.
Provides diagnostic solutions such as GI Genius for colorectal polyp detection.
Manufactures injectable compositions like Eleview for gastrointestinal endoscopic procedures.
Markets Aemcolo/Relafalk for treating traveler's diarrhea and other gastrointestinal conditions.
Develops androgen receptor inhibitors like Winlevi for acne vulgaris.

CMOPF如何赚钱？

Generates revenue through the sale of specialty pharmaceutical products.
Engages in licensing agreements to expand market reach and product offerings.
Invests in research and development to innovate and enhance its product pipeline.
Utilizes partnerships to access new markets and accelerate product development.
Focuses on high-margin products to improve overall profitability.

Healthcare providers and hospitals seeking advanced gastroenterology treatments.
Patients suffering from gastrointestinal disorders requiring effective therapies.
Pharmacies and distributors that supply specialty pharmaceuticals.
Healthcare systems looking for innovative diagnostic solutions.
Research institutions involved in clinical studies of gastrointestinal diseases.

Strong intellectual property portfolio protecting key products from generic competition.
Innovative technologies like AI in diagnostics, differentiating from competitors.
Established relationships with healthcare providers and distributors enhancing market access.
Diverse product portfolio addressing various gastrointestinal conditions, reducing risk.
Experienced management team with a track record in pharmaceutical development.

什么因素可能推动CMOPF股价上涨？

Upcoming: Launch of new products targeting gastrointestinal disorders expected in the next 12 months.
Ongoing: Continuous development of AI technology in diagnostics enhancing product offerings.
Ongoing: Strategic partnerships expanding market access and product distribution.
Upcoming: Potential regulatory approvals for new therapies in the pipeline.
Ongoing: Increasing demand for gastroenterology treatments driven by rising disease prevalence.

CMOPF的主要风险是什么？

Potential: Regulatory hurdles impacting product approvals and market entry.
Ongoing: Intense competition from established players in the pharmaceutical industry.
Potential: Patent expirations leading to increased generic competition.
Ongoing: Economic downturns affecting healthcare spending and patient access to treatments.

CMOPF的核心优势是什么？

Innovative product portfolio addressing critical healthcare needs.
Strong gross margins indicating operational efficiency.
Established presence in the gastroenterology market with a growing customer base.
Strategic partnerships enhancing product offerings and market access.

CMOPF的劣势是什么？

Negative profit margin indicating current operational challenges.
High P/E ratio suggesting market caution regarding profitability.
Dependence on a limited number of products for revenue generation.
Potential regulatory hurdles impacting product approvals and market entry.

CMOPF有哪些机遇？

Growing demand for gastrointestinal treatments driven by rising disease prevalence.
Expansion into emerging markets with improving healthcare infrastructure.
Advancements in AI technology providing new diagnostic capabilities.
Potential for product line diversification through ongoing R&D efforts.

CMOPF面临哪些威胁？

Intense competition from other pharmaceutical companies in the gastroenterology space.
Risk of patent expirations leading to generic competition.
Regulatory changes affecting drug approval processes and market access.
Economic downturns impacting healthcare spending and patient access to treatments.

CMOPF的竞争对手是谁？

RedHill Biopharma Ltd. — Focuses on gastrointestinal diseases with a diverse product pipeline. — (CHIZF)
Evotec SE — Specializes in drug discovery and development across multiple therapeutic areas. — (EVOTF)
Glenmark Pharmaceuticals Ltd. — Offers a range of generic and specialty pharmaceuticals. — (GNTLF)
KSP Holdings — Engaged in developing specialty pharmaceuticals for various conditions. — (KSPHF)
Lannett Company, Inc. — Focuses on generic pharmaceuticals with a growing specialty segment. — (LJUIF)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Giovanni Di Napoli
Headquarters: Dublin, IE
Employees: 321
Founded: 2017

AI Insight

AI analysis pending for CMOPF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cosmo Pharmaceuticals N.V. do?

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing innovative products for gastroenterology and endoscopy. The company offers a range of treatments for conditions such as ulcerative colitis and provides diagnostic solutions using advanced technologies like artificial intelligence.

What do analysts say about CMOPF stock?

Analysts generally view Cosmo Pharmaceuticals N.V. as a company with strong growth potential due to its innovative product pipeline and strategic partnerships. Key valuation metrics indicate a cautious outlook given the negative profit margin, but the company's focus on high-demand therapeutic areas is seen as a positive factor.

What are the main risks for CMOPF?

Main risks for Cosmo Pharmaceuticals N.V. include regulatory challenges that could delay product approvals, intense competition from other pharmaceutical companies, and the potential impact of patent expirations leading to generic competition. Additionally, economic factors may influence healthcare spending, affecting the company's revenue.